UBS Group
ELVN icon

UBS Group’s Enliven Therapeutics ELVN Stock Holding History

UBS Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4M Buy
342,115
+58,571
+21% +$2.49M ﹤0.01% 2844
2026
Q1 		$11.1M Buy
283,544
+225,676
+390% +$6.25M ﹤0.01% 3213
2025
Q4 		$891K Sell
57,868
-21,640
-27% -$431K ﹤0.01% 5674
2025
Q3 		$1.63M Sell
79,508
-58,772
-43% -$1.18M ﹤0.01% 5154
2025
Q2 		$2.77M Buy
138,280
+67,844
+96% +$1.28M ﹤0.01% 4472
2025
Q1 		$1.39M Sell
70,436
-16,752
-19% -$361K ﹤0.01% 5011
2024
Q4 		$1.96M Buy
87,188
+59,506
+215% +$1.54M ﹤0.01% 4731
2024
Q3 		$707K Buy
27,682
+7,564
+38% +$175K ﹤0.01% 4960
2024
Q2 		$470K Sell
20,118
-6,717
-25% -$141K ﹤0.01% 5048
2024
Q1 		$472K Buy
+26,835
New +$412K ﹤0.01% 5250
2023
Q4 		– Sell
-105
Closed -$1.43K – 9445
2023
Q3 		$1.43K Buy
105
+24
+30% +$404 ﹤0.01% 7943
2023
Q2 		$1.65K Sell
81
-253
-76% -$5.11K ﹤0.01% 7879
2023
Q1 		$7.32K Sell
334
-377
-53% -$7.67K ﹤0.01% 7817
2022
Q4 		$11.6K Buy
+711
New +$11.4K ﹤0.01% 8374
2022
Q1 		– Sell
-1,121
Closed -$10K – 10406
2021
Q4 		$10K Buy
+1,121
New +$14.7K ﹤0.01% 8771
2021
Q3 		– Sell
-536
Closed -$17K – 9673
2021
Q2 		$17K Buy
536
+126
+31% +$3.91K ﹤0.01% 7504
2021
Q1 		$14K Buy
410
+131
+47% +$6.66K ﹤0.01% 7671
2020
Q4 		$25K Buy
+279
New +$23.4K ﹤0.01% 6775
2020
Q3 		– Sell
-391
Closed -$43K – 8081
2020
Q2 		$43K Buy
+391
New +$43.8K ﹤0.01% 5979

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

UBS Group's ELVN Position: Q2 2026 in Review

UBS Group increased its Enliven Therapeutics (ELVN) stake by 21% in Q2 2026, buying an estimated $2.49M and bringing the position to 342,115 shares worth $17.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2844.

UBS Group first reported a position in ELVN in Q2 2020 and has held it in 19 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • UBS Group held 342,115 shares of Enliven Therapeutics worth $17.4M as of Q2 2026.
  • UBS Group bought 58,571 Enliven Therapeutics shares in Q2 2026, an estimated $2.49M.
  • Enliven Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2844 holding.
  • UBS Group first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.